Key result
Pre-treatment with irbesartan (20 mg/kg) significantly normalized biochemical parameters and prevented the development of streptozotocin-induced diabetic nephropathy in rats.
Why the study?
Does irbesartan prevent biochemical and functional changes in STZ-induced diabetic nephropathy in rats?
Does irbesartan prevent biochemical and functional changes in STZ-induced diabetic nephropathy in rats?
Irbesartan demonstrates a preventive role against the development of biochemical and functional renal abnormalities in a rat model of diabetic nephropathy.
Does not support clinical use; leaves open translation of rat findings to human diabetic nephropathy.
BACKGROUND: Diabetic nephropathy (DN) is one of the most common causes of end-stage renal failure. The pathogenesis of progressive renal damage is multifactorial and the mechanism by which hyperglycemia causes microangiopathy in diabetic glomeruli is still poorly understood. Because the renin angiotensin system has been reported to be an important contributory factor in the pathophysiology of DN, exogenous administration of angiotensin II receptor antagonist may be beneficial in counteracting some biochemical or functional changes of DN. AIMS: The present study was therefore undertaken to evaluate the preventive role of irbesartan in streptozotocin (STZ)-induced DN in rats. METHODS AND MATERIAL: STZ-induced DN in rats was assessed biochemically by measuring urine volume, protein and electrolytes as well as blood urea and creatinine clearance. RESULTS: Marked hyperglycemia, polyuria, proteinuria and uremia along with a reduction in urine electrolytes and creatinine clearance were observed in STZ diabetic rats. Pre-treatment with irbesartan (20 mg/kg, p.o. 5 days prior to STZ and continued for 16 weeks) also significantly altered these parameters towards normal, except blood glucose. CONCLUSION: Pre-treatment with insulin reversed the parameters of DN. The data suggest that irbesartan prevents the development of STZ-induced DN in rats.
No takes yet. Share an insight, caveat, or question.
Vaishya et al. (2009) studied Diabetic nephropathy. Irbesartan vs. Untreated STZ diabetic rats was evaluated on Biochemical parameters including urine volume, protein, electrolytes, blood urea, and creatinine clearance. Pre-treatment with irbesartan (20 mg/kg) significantly normalized biochemical parameters and prevented the development of streptozotocin-induced diabetic nephropathy in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: